^{Source: Newsweek}

On Wednesday, April 9, 2025, the pharmaceutical sector experienced a significant downturn following President Donald Trump's announcement of impending tariffs on imported drugs. The proposed 25% levy aims to encourage domestic manufacturing but has raised concerns about potential supply chain disruptions and increased medication costs.​

U.S. Pharmaceutical Giants Experience Sharp Declines

Major U.S.-based pharmaceutical companies saw their stock prices tumble in response to the tariff news:​

• Eli Lilly (LLY): Shares declined by approximately 4.3%, closing at $695.32.​
• AbbVie (ABBV): Experienced a 3.7% drop, ending the day at $169.15.​
• Bristol Myers Squibb (BMY): Fell by 4%, with shares priced at $50.95.​
• Regeneron Pharmaceuticals (REGN): Decreased by 2.2%, closing at $544.62.​

Other industry leaders, including Merck (MRK), Pfizer (PFE), Johnson & Johnson (JNJ), and Amgen (AMGN), also reported losses ranging from 2% to 3%.​

International Pharmaceutical Companies Also Affected

The tariff announcement had a global impact, with foreign-based pharmaceutical firms experiencing notable stock declines:​

• AstraZeneca (AZN): Shares dropped by 4.2%, closing at $62.17.​
• GlaxoSmithKline (GSK): Fell by 3.9%, ending at $32.815.​

These companies, heavily reliant on the U.S. market, face potential challenges in maintaining their export levels amid the proposed tariffs.​

Presidential Push for Domestic Manufacturing

President Trump emphasized the need to reduce dependence on foreign pharmaceutical production, stating that the U.S. would implement a "major" tariff on imported medications to incentivize companies to relocate manufacturing domestically. This move aligns with his broader strategy to bolster American industries and reduce trade deficits.​

Industry Concerns Over Supply Chain Disruptions

Analysts and industry executives have expressed apprehension regarding the feasibility of reshoring pharmaceutical manufacturing. The process involves complex supply chains and significant investment in specialized facilities. Evan Seigerman, an analyst at BMO Capital Markets, noted that the tariffs are unlikely to prompt immediate shifts in manufacturing locations due to these complexities.​

Potential Impact on Drug Prices and Innovation

Trade groups warn that the proposed tariffs could lead to increased medication costs for consumers and exacerbate existing drug shortages. The Association for Accessible Medicines highlighted that generic manufacturers operate on thin profit margins and may struggle to absorb additional costs, potentially leading to market exits and reduced competition.​

Furthermore, companies like Eli Lilly have voiced concerns about the tariffs' impact on research and development budgets. CEO Dave Ricks indicated that absorbing tariff costs might necessitate cuts in staff or R&D investments, potentially hindering innovation in the pharmaceutical sector.​

Legislative Response and Industry Outlook

A group of House Democrats has urged the administration to reconsider the tariffs, citing potential negative consequences for U.S. patients, including treatment delays and increased healthcare costs. The lawmakers emphasized the importance of protecting medical supply chains to ensure patient access to essential medications.​

While some pharmaceutical companies have announced plans to expand U.S. manufacturing—Eli Lilly committed over $50 billion since 2020, and Johnson & Johnson planned $55 billion in investments—industry leaders caution that reshoring efforts require time and substantial resources.​

As the situation develops, stakeholders will closely monitor the administration's trade policies and their implications for the pharmaceutical industry, healthcare costs, and patient access to medications.​

‍